TABLE 4.
Estimated Recurrence and Progression Rates for Each AUA NMIBC Risk Category at 6, 12, and 24 Months Based on Adjuvant Treatment Given
| Risk Category/Treatment | Recurrence Rate (%) | Progression Rate (%) | ||||
|---|---|---|---|---|---|---|
| 6 mo | 12 mo | 24 mo | 6 mo | 12 mo | 24 mo | |
| Low risk / TURBT alone | 15 | 20 | 25 | 0 | 1 | 1 |
| Low risk / TURBT 1 perioperative chemo | 5 | 10 | 15 | 0 | 1 | 1 |
| Intermediate risk / TURBT 1 chemo | 20 | 30 | 40 | 2 | 3 | 5 |
| Intermediate risk / TURBT 1 BCG (induction and maintenance) | 20 | 25 | 30 | 2 | 3 | 4 |
| High risk / TURBT 1 BCG (induction and maintenance) | 20 | 25 | 30 | 3 | 5 | 10 |
Adapted from Kamat AM.29
Rates for all intermediate- and high-risk patients are based on BCG naive.
AUA, American Urological Association; BCG, bacillus Calmette-Guérin; NMIBC, non-muscle-invasive bladder cancer; TURBT, transurethral resection of bladder tumor.